EHR-integrated remote BP monitoring was evaluated in a primary care Medicare population to assess uptake and initial effects on hypertension management.
"What we really wanted to do was to put into practice what Medicare has made available as a new paid service, which is remote physiological monitoring, or remote patient monitoring (RPM)," said Steve Persell, MD, MPH in a recent interview. "We wanted to apply that to hypertension in the primary care setting."
Persell talked with Patient Care about a pilot study he led that integrated the Omron VitalSightTM RPM with electronic health records (EHR) in 2 primary care practices to assess its use in transmitting blood pressure readings directly to the clinicians' EHR inbox and subsequent effects on hypertension management. The results were presented at the American Hear Association Scientific Sessions 2021.
Persell describes the study's findings as well as what he sees as the challenges to scaling remote monitoring effectively, a process that will likely involve restructuring insurance templates, office workflows, and patient expectations. He, for one, has already started his part.
Stephen D Persell, MD, MHP is professor of medicine, Division of General Internal Medicine and Geriatrics, Northwestern University Feinberg School of Medicine and director of the Center for Primary Care Innovation at Northwestern Medicine.
Persell S, Anthony L, Peprah Y, et al. A pilot study of remote patient monitoring for hypertension in primary care. Abstract presented at the American Heart Association Scientific Sessions 2021, held virtually, November 13-15, 2021.
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
September 9th 2025Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.